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Introduction: Malignant gliomas are a heterogeneous group of primary central nervous system 
neoplasms that represent less than 2% of all cancers yet carry a significant burden to society. 
They are frequently associated with considerable and progressive neurological disability and are 
ultimately intractable to all forms of treatment. Temozolomide (TMZ) is a new second generation 
DNA alkylating agent that has become part of malignant astrocytoma management paradigms 
because of its proven efficacy, ease of administration, and favorable toxicity profile.
Aims: To review the role of TMZ in the management of malignant astrocytomas (World Health 
Organization grades III and IV) including newly diagnosed (n) and recurrent (r) anaplastic 
astrocytomas (AA) and glioblastomas.
Evidence review: A series of pivotal clinical trials have established a role for TMZ in the 
treatment of malignant astrocytomas. A large phase II trial examining the role of TMZ in rAA 
showed a response rate of 35%, and a 6-month progression-free survival of 46%. This led to 
the accelerated approval of TMZ by the FDA and the EU for the treatment of rAA. Evidence 
for a role of TMZ in nAA is currently limited but research is ongoing in this area. The role of 
TMZ in the management of glioblastoma at the time of recurrence (rGBM) is less impressive 
but evidence for its activity was demonstrated in two large phase II trials that led to the approval 
of TMZ for this indication in Europe and Canada but not in the US. A recent large prospective 
randomized phase III trial showed that the addition of TMZ during and after radiation therapy 
(RT) in newly diagnosed (nGBM) patients prolonged median overall survival by 2.5 months; 
perhaps more importantly, the 2-year survival rate for patients receiving TMZ and RT was 26% 
compared with 10% for those receiving RT alone. Concurrent TMZ with RT followed by adjuvant 
TMZ has become the standard of care for nGBM patients. Based on the evidence presented in 
this trial, TMZ received approval from the FDA and the EU for patients with nGBM in 2005.
Place in therapy: There is evidence to support the use of TMZ for the following diseases in 
the order of most to least convincing: nGBM, rAA, rGBM, and nAA. This order may quickly 
change as more trials are being designed and implemented, particularly with novel TMZ dosing 
schedules.
Keywords: temozolomide, evidence, malignant astrocytoma, glioma, anaplastic astrocytoma, 
glioblastoma
Scope, aims, and objectives
In the US, temozolomide (TMZ; Temodar®, Temodal®, Schering-Plough Corporation) is 
indicated for recurrent anaplastic astrocytoma (rAA) and newly diagnosed glioblastoma 
(nGBM), and in Europe for nGBM, recurrent glioglastoma (rGBM), and rAA. This 
review summarizes the disease background, current therapy options, and unmet medical 
needs for patients with malignant gliomas, and outlines the current evidence for the role Core Evidence 2009:4 94
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of TMZ in the management of malignant gliomas. Outcomes 
evaluated included objective radiographic response, progres-
sion-free survival at 6 months (PFS6m), median overall 
survival (mOS), 2-year survival, health-related quality of life 
(HRQoL), and the safety/tolerability profile of TMZ when 
used for the above indications.
Methods
The English language medical literature was searched in the 
following databases.
•  Medline
•  EMBase
•  Cochrane reviews
Core evidence place in therapy summary for temozolomide (TMZ) in malignant astrocytomas
Outcome measure Evidence Implications
Patient-oriented evidence
The addition of TMZ to standard rT followed by 
adjuvant TMZ increases the percentage of patients 
with PFS at 6 months (53.9% for TMZ/rT + TMZ vs 
36.4% for rT alone, a 17.2% increase)
Clear TMZ increases the percentage of progression-free 
nGBM patients
Concurrent TMZ/rT followed by adjuvant TMZ 
increases mOS by 2.5 months compared with rT 
alone in nGBM patients
Clear TMZ results in improved survival among nGBM 
patients
Concurrent TMZ/rT followed by adjuvant TMZ 
increases 2-year survival from 10% to 24% for 
nGBM patients treated with rT alone
Clear TMZ increases the odds of nGBM patients surviving 
to the 2-year time point
Concurrent TMZ/rT followed by adjuvant TMZ 
results in a 37% reduction in the risk of death for 
nGBM patients compared with rT alone
Clear TMZ reduces the risk of death among nGBM patients
The HrQoL scores among nGBM patients treated 
with concurrent TMZ/rT followed by adjuvant TMZ 
were not inferior to the HrQoL scores derived 
from patients treated with rT alone
Clear TMZ does not reduce the quality of life among nGBM 
patients
The PFS6m for rGBM patients treated with TMZ 
was 21% compared with a PFS6m of only 8% for 
patients treated with PCB, a 13% increase
Clear TMZ improves the percentage of progression-free 
rGBM patients at 6 months compared with PCB
TMZ does not seem to improve survival among 
rGBM or rAA patients
Limited TMZ does not improve survival when used for 
recurrent disease
TMZ treatment results in improved HrQoL scores 
when used for both rGBM and rAA patients
Clear TMZ improves patient quality of life when used for 
recurrent disease
Disease-oriented evidence
nGBM patients treated with neoadjuvant TMZ 
achieve an Orr of 20%
Moderate TMZ given prior to rT for nGBM patients results in 
radiographic improvement that usually correlates with 
clinical improvement
rGBM patients treated with TMZ did not achieve an 
improved Orr compared with other agents
Limited TMZ given to rGBM patients does not result in a 
better radiographic response compared to other 
agents
TMZ possibly results in a higher Orr for rAA 
patients (35%) compared with only a 14% Orr 
for patients treated with other chemotherapeutic 
agents. Because of the differences in baseline patient 
characteristics for those two trials, no definitive 
conclusions can be drawn
Limited TMZ may result in a more significant radiographic 
improvement when given to rAA patients compared 
with other agents
Economic evidence
TMZ is an expensive new agent but the added costs 
may be justified by the improved survival among 
nGBM patients
Limited Despite the lack of conclusive cost-effectiveness data, 
TMZ should be considered especially from nGBM 
patients
The cost effectiveness of TMZ in recurrent disease 
is not clear at this point
Limited One study concludes that TMZ may not be cost 
effective in recurrent disease compared with 
lomustine
Abbreviations: HrQoL, health-related quality of life; mOS, median overall survival; nGBM, newly diagnose survival; glioblastoma; Orr, objective radiographic response; 
PCB, procarbazine; PFS, progression-free survival; PFS6m, progression-free survival at 6 months; rAA, recurrent anaplastic astrocytoma; rGBM, recurrent glioblastoma; 
rGBM, recurrent glioblastoma; rT, radiotherapy.Core Evidence 2009:4 95
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The search terms used were temozolomide, glioblastoma, 
and anaplastic astrocytoma, and the records were limited 
to clinical trials, meta analyses, practice guidelines, and 
randomized controlled trials. The cutoff dates were from 
beginning through to March 25, 2008 (Table 1).
Disease overview
Epidemiology
According to the Central Brain Tumor Registry of the 
US (CBTRUS) database, the number of reported cases of 
glioblastoma (GBM) between 1998–2002 was 12 943.1 
The age-adjusted incidence of GBM was 3.05 [confidence 
interval (CI): 3.00, 3.10] and the median age at diagnosis was 
64 years (CBTRUS 2006). The number of reported anaplastic 
astrocytoma (AA) cases during the same period was 2029 and 
the age-adjusted incidence was 0.47 (CI: 0.45, 0.49), with a 
median age at diagnosis for AA of 51 years.1
In the registry, GBM was the most common subtype of gli-
oma and represented 20.3% of all malignant and nonmalignant 
brain tumors, and 50.7% of all glioma subtypes. In contrast, 
AA represented only 3.2% of all malignant and nonmalignant 
brain tumors, and 7.9% of all gliomas. The age-adjusted 
incidence rates for both GBM and AA were higher among 
males compared with females (3.86 per 100 000 person years 
in males versus 2.39 per 100 000 person years in females 
for GBM, and 0.56 per 100 000 person years among males 
versus 0.38 per 100 000 person years among females for AA). 
The incidence of both AA and GBM among white people was 
almost double the rate among black people.1
risk factors and etiology
Familial, environmental, and genetic factors have been 
implicated in the development of astrocytomas. Most reported 
studies lack statistical power to identify unequivocally any 
single risk factor for the development of malignant gliomas.
Familial factors
Malignant astrocytomas are occasionally found at a higher 
frequency in families where several other malignancies 
are prevalent. Such familial cancer syndromes are due to 
germline mutations and include Li-Fraumeni syndrome, 
neurofibromatosis, Turcot syndrome, and multiple enchon-
dromatosis.2 Interestingly, neurofibromatosis type-1 is 
due to a mutation on chromosome 17, which also harbors 
the p53 gene implicated in the genesis of many malignant 
gliomas.3
Environmental factors
Environmental factors that contribute to the development 
of malignant gliomas are notoriously difficult to ascertain 
with confidence. Because of the relatively low incidence of 
malignant gliomas, studies are able to establish a possible but 
inconclusive relationship between environmental exposures 
and the development of malignant gliomas. Ionizing 
radiation, however, has unequivocally been implicated in 
the genesis of secondary brain malignancies including AA 
and GBM after a minimallatency period of approximately 
10 years.4,5 For instance, the routine use of prophylactic 
irradiation for leukemia has resulted in an increased risk of 
secondary gliomas in this patient population.6
On the other hand, there has been considerable debate as 
to whether high-energy electromagnetic radiation generated 
by the use of cellular phones contributes to the genesis of 
malignant gliomas. Results are conflicting but several studies 
have concluded that cellular telephones do not seem to be 
related causally to the development of malignant gliomas.8 
Long-term follow up studies may still be needed however 
to settle this debate.
Genetic mutations
Gliomas are believed to arise as a result of a series of genetic 
aberrations that slowly accumulate over time.9 Theoretically, 
asthenumber of geneticmutationsincreases, tumors may prog-
ress from low-grade to higher grade phenotypes and geno-
types. Molecular profiling has allowed the characterization of 
Table 1 Evidence base included in the reviewa
Category Number of records
Full papers
initial search 96
  records included 58
  records excluded 38
Search update
  Hand search of cross-references 29
Preclinical evidence 9
Level 1 evidence (systematic 
review, meta analysis)
2
Level 2 clinical evidence (rCT) 9
Level  3 clinical evidence 45
  Trials other than rCT 42
  Case reports 5
Economic evidence 10
Notes: aSome references fall under multiple categories.
For definition of levels of evidence, see the Core Evidence website (http://www.
dovepress.com/core-evidence-journal).
Abbrevation: rCT, randomized controlled trial.Core Evidence 2009:4 96
Omar and Mason Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
genetic mutations within brain tumor samples. GBMs can arise 
as a result of progression from low-grade astrocytomas, also 
known as secondary GBM, or de novo, also known as primary 
GBM. Primary (de novo) GBM represents approximately 
80% of all GBMs. The genetic mutations within each of 
those entities may differ markedly. For example, mutation 
of the proapoptotic p53 gene located on chromosome 17 is 
believed to be the primary event involved in the genesis of a 
low-grade astrocytoma and is found with a higher incidence 
among secondary GBM tumor samples.3 Consequently, the 
mutated p53 gene is found with increasing frequency (65%) 
in diffuse [World Health Organization (WHO) grade II] 
astrocytomas.10 This molecular derangement typically results 
in defective apoptosis and allows for uncontrolled cellular 
proliferation.11 In addition, overexpression of the platelet-
derived growth factor receptor is found in over 60% of low-
grade astrocytomas.11 The further sequential accumulation 
of genetic mutations in the form of loss of heterozygosity 
for chromosome 10q (LOH 10q), as well as mutation of the 
tumor suppressor retinoblastoma gene, has been observed in 
the progression of low-grade diffuse astrocytomas (WHO 
grade II) to AA (WHO grade III).12 Several genetic mutations 
are found in both GBM and AA or GBM arising from AA, but 
with variable frequency. For example, p53 mutation is far less 
frequent in primary GBM (∼25%) when compared with AA 
(∼50%) and secondary GBM (∼65%).13 Additionally, LOH 
10q is found in only ∼8% of GBM that have evolved from 
AA, compared with ∼50% of primary GBM.14 The amplifi-
cation of the epidermal growth factor receptor seems more 
important in primary GBM (∼36%) than in GBM that arises 
from an underlying AA (∼8%).11 These differences may aid in 
the diagnosis and prognosis of AA and GBM, and potentially 
identify targeted therapies to specific tumor subtypes based 
on genetic features.
Histologic subtypes
Astrocytomas are classified in ascending order of aggres-
siveness into WHO grades I–IV.15 Malignant astrocytomas 
fall under the more aggressive WHO grades III and IV 
and include AA (WHO grade III) and the most aggressive 
astrocytic neoplasm, GBM, which is classified as a grade IV 
tumor in the WHO grading scheme (Figure 1). GBM is also 
the most frequently encountered primary brain malignancy 
in the adult population.11,16
Goals of therapy
The goals of surgery for nGBM and nAA differ from those 
for recurrent disease. The goals of surgery for nGBM and 
nAA include providing tissue for an accurate pathologic 
diagnosis as well as tumor cytoreducation that can alleviate 
symptoms and reduce neurological deficits. For recurrent 
disease, the goal is usually tumor debulking alone. Whenever 
surgical resection is possible, the goal is maximal feasible 
tumor reduction provided that this can be achieved safely. 
Postoperative radiotherapy (RT) and chemotherapy are 
given to treat any residual disease and achieve a durable 
remission.
Despite multimodality treatment, patients with malignant 
gliomas invariably relapse, and at this time treatment goals 
are palliative in nature to the extent that therapeutic efforts 
are focused on delaying further tumor progression and 
preserving quality of life.
Evaluating response to therapy
In the earlier phase I and II trials evaluating the safety and 
efficacy of TMZ, an objective radiographic response was 
often used as a primary endpoint.17,18 Recently, PFS6m 
has been utilized as a new primary outcome measure in 
neurooncology because objective radiographic responses are 
uncommon in trials of new agents for recurrent malignant 
glioma, and because disease stabilization (radiographic or 
clinical) has been perceived as a valuable and treatment-
specific outcome. The use of mOS and HRQoL have also 
been implemented as useful and informative secondary 
outcomes. To this extent, quality-adjusted life-year (QALY) 
is an emerging indicator incorporating both quantity and 
quality of life as a single parameter.19,20 In economic analy-
ses, the cost of QALYs gained by administering a drug is 
an important measure of the cost effectiveness of the drug 
and may play an important role in drug reimbursement 
decisions. QALY is calculated by the duration spent in a 
health state (in years) weighted by the preference to that 
state (utility).
The following discussion defines the parameters 
employed as endpoints in the trials evaluating TMZ activity 
in malignant astrocytomas.
WHO grade lll
–AA
a
WHO grade lV 
–GBM
Malignant astrocytomas
Figure 1 WHO classification scheme for malignant astrocytomas. 
Notes:   aSome AAs containing oligodendroglial components are classified as anaplastic 
oligoastrocytomas (AOA). 
Abbreviations:   AA, anaplastic astrocytoma; GBM, glioblastoma multiforme; wHO, 
world Health Organization.Core Evidence 2009:4 97
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Objective radiographic response
One of the most widely adopted measures of tumor response 
is the objective radiographic response (ORR) according to the 
criteria proposed by MacDonald et al.21 Imaging modalities 
include contrasted computerized tomography (CT) scans of 
the brain or gadolinium-enhanced magnetic resonance (MR) 
scans, and these scans are obtained at various time points 
following treatment. In this scale, the two largest perpen-
dicular diameters of the enhancing mass are multiplied and 
the product is then used as a baseline measure of the “tumor 
size.” Four response categories are identified on contrast-
enhanced CT or MR scans.
•  Partial response (PR): a 50% decrease in tumor size com-
pared to a prior scan at least 1 month apart, on a stable 
(2 weeks) dose of steroids, and neurologically stable 
or improving.
•  Complete response (CR): the complete disappearance of 
the contrast-enhancing mass.
•  Progressive disease: an increase in tumor size 25% 
compared to a prior scan at least 1 month apart, on a 
stable (2 weeks) dose of steroids, and neurologic 
worsening.
•  Stable disease: all other response categories.
Some of the drawbacks associated with this technique 
include a relatively wide interobserver variability of the 
measurements (hence the importance of a central radiology 
review of all scans assessed in a clinical trial), the occa-
sional presence of multifocal disease that can be difficult 
to measure, variations associated with scanning techniques 
(such as dose of contrast medium), and variations in the 
timing of contrast injections relative to image acquisition. 
Furthermore, since tumors are three-dimensional masses, 
a bidimensional quantitative measure often fails to reflect 
the true size and dimensions of the tumor. In addition, 
some gliomas enhance heterogeneously and may contain 
nonenhancing areas that may not be included in the mea-
surements, while conversely some contrast-enhancing areas 
may not represent tumor, but rather postsurgical changes 
or radiation effect. Despite these limitations, the ORR is 
a commonly employed endpoint used to assess efficacy 
of chemotherapeutic agents for the treatment of malignant 
astrocytomas.
Progression-free survival
PFS6m
PFS6m is defined as the percentage of patients who are alive 
and progression-free clinically and radiographically 6 months 
after the start of an intervention.
Median PFS
The median PFS is the median survival for a group of 
patients who remain progression-free after the initiation of 
an intervention.
Overall survival
mOS
The mOS is defined as the median time from start of treatment 
to death among a group of trial patients.
2-year survival
The 2-year survival is defined as the percentage of patients 
alive 2 years after the beginning of an intervention.
HrQoL
HRQoL is assessed using validated quality of life instruments 
such as the European Organisation for the Research and 
Treatment of Cancer (EORTC) quality of life questionnaires 
Core-30 and the EORTC brain cancer module (BN-20).22,23 
The seven domains commonly utilized for the assessment 
of quality of life changes in trials involving brain tumor 
patients include global HRQoL and physical role, cognitive, 
emotional, and social functioning. A 10 point change on a 
0-100 point scale is considered significant in the determina-
tion of changes in HRQoL status.24,25 Commonly, quality of 
life improvements correlate with radiographic response, and 
deterioration in quality of life correlates with radiographic 
progression. A drug that is capable of delaying time to tumor 
progression may therefore favorably impact quality of life 
in a clinically meaningful way, even if it fails to prolong 
overall survival.26
Current treatment options
nGBM and nAA
Patients with nGBM are treated with the three common 
modalities available for the treatment of all gliomas: surgery, 
RT, and chemotherapy. The first step in the management of 
gliomas is to obtain a pathologic diagnosis either through a 
stereotactic biopsy or open resection. Ideally, the surgeon 
attempts to perform a gross total resection of the tumor 
with the exception of deep-seated, inaccessible tumors, and 
tumors located in eloquent brain regions where resection may 
result in significant neurologic compromise. Postoperatively, 
involved field radiation is given to the enhancing region 
plus a 2–3 cm margin. RT is typically given in fractions of 
2 Gy each for 6 weeks (60 Gy total).27 Postoperative RT 
and chemotherapy are given to treat residual disease that is 
invariably present following surgery.28Core Evidence 2009:4 98
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For patients with nAA, the current standard treatment 
options include maximal feasible surgical resection 
followed by involved field, conformal RT similar to the 
dose schedule prescribed for nGBM (60 Gy in 30 fractions 
of 2 Gy each). Although there is scant evidence to support 
a role for adjuvant chemotherapy in the management of 
AA, many neurooncologists frequently prescribe adjuvant 
chemotherapy for patients with this disease.
rGBM and rAA
Patients with GBM invariably exhibit disease recurrence, even 
among those with a complete response following successful 
treatment. At the time of disease recurrence, patients are 
commonly prescribed second-line chemotherapy agents, 
most often a nitrosourea.29 Other chemotherapeutic agents 
utilized in the salvage setting include nitrosoureas, etoposide, 
cyclophosphamide, and platinum compounds.30–32
A second craniotomy with tumor resection is typically 
reserved for reasonably well patients with tumors that have 
caused worsening neurologic deficits or a rise in intracranial 
pressure.33 Repeat irradiation is also a treatment option at the 
time of relapse but this is seldom prescribed because of the 
markedly increased risk of radionecrosis and leukoencepha-
lopathy associated with repeat irradiation.34,35 Some of the 
newer RT techniques such as intensity-modulated radiation 
therapy and radiosurgery may minimize such risks but these 
remain experimental approaches for recurrent gliomas.36
Unmet needs
Malignant astrocytomas have long been considered amongst 
the most resistant cancers to therapeutic intervention. Despite 
advances in surgical and RT techniques over the last few 
decades, these therapies have had minimal impact on survival 
statistics. Attempts to improve survival with the addition of 
adjuvant chemotherapy have generally been disappointing, 
and numerous large phase III trials examining this matter have 
failed to show a survival advantage for chemotherapy-treated 
patients.37–40 Despite these generally negative results, a sys-
tematic meta analysis of 12 randomized trials demonstrated 
a small, but statistically significant, survival advantage for 
patients treated with adjuvant chemotherapy (a 5% increase 
in 2-year survival from 15% to 20%).41
Clinical evidence with TMZ
TMZ is an orally active alkylating agent that has shown 
activity in the treatment of malignant gliomas. Unlike many 
other chemotherapeutic agents, it readily crosses the blood-
brain barrier and has a well tolerated safety profile. Until 
recently, the nitrosoureas were the first-line agents used for 
the treatment of malignant gliomas despite their minimal effi-
cacy and significant toxicity. TMZ on the other hand has now 
become the first-line agent particularly for the treatment of 
GBM because of its proven benefit and good safety profile.
TMZ pharmacology
TMZ is a second generation imidazotetrazinone derivative. 
It undergoes a series of spontaneous reactions under 
physiologic conditions beginning with its hydrolysis into 
its active metabolite 5-(3-methyl-1-triazen-1-yl) imidazole-
4-carboxamide, which further undergoes degradation into 
a methyldiazonium ion. This ion is the active compound 
that transfers a methyl group to DNA and thus affects the 
cytotoxic activity of TMZ. Although the final degradation 
product, 4-amino-5-imidazole-carboxamide is eliminated 
through the kidney, no TMZ dose adjustments are usually 
required for patients with impaired renal function.42
TMZ exerts its cytotoxic action via DNA methylation at 
the N-7 and O-6 positions of guanine, and the O-3 position 
of adenine. Although methylation of the O-6 position of 
guanine represents only a small fraction of the total DNA 
lesions induced by TMZ, it remains the major effector of its 
cytotoxic action. Methylation of guanine at the O-6 position 
results in “mismatch” incorporation of thymidine instead of 
cytosine.
This error is recognized by the mismatch repair (MMR) 
enzyme system that attempts to excise thymidine. Since 
guanine methylation persists, a series of futile replication 
and repair cycles ensue, ultimately resulting in apoptotic 
cell death. In the presence of the DNA repair enzyme 
O-6-methlguanine-DNA methyltransferase (MGMT, a 
DNA repair enzyme that removes methyl adducts at the 
O-6 position of guanine added by TMZ),43 the methylation 
of guanine can be repaired thereby allowing the cells to 
escape TMZ-induced cell death. Therefore, for TMZ to 
exert its cytotoxic action, a cell needs an intact MMR system 
and deficient or low MGMT enzyme levels. Conversely, a 
deficient MMR system coupled with high MGMT expression 
levels may mediate TMZ resistance.44,45
TMZ toxicity profile
Drug-related toxicities are typically graded according to 
the National Cancer Institute Common Toxicity Criteria 
(NCI-CTC) version 3.0.46 The most common toxic side 
effects associated with TMZ are nausea, vomiting, fatigue, 
and hematologic toxicity. According to the NCI-CTC, toxic 
side effects are graded on a scale of 1–5. Tables 2 and 3 Core Evidence 2009:4 99
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summarize the various grades of severity of some of the more 
common side effects associated with TMZ.
There are single case reports describing instances of 
severe toxic side effects associated with TMZ treatment. One 
report describes the development of listeria, brain abscess, 
pneumocystis pneumonia, and Kaposi’s sarcoma in a GBM 
patient treated with TMZ.47 Another report describes the 
development of organizing pneumonitis associated with 
temozolomide.48
Objective radiographic response
nGBM and nAA
TMZ has been assessed in several clinical trials for the 
treatment of nGBM as a single agent. Response rates varied 
depending on the dosing schedule utilized in these trials.
A phase II multicenter study examined the role of 
neoadjuvant TMZ (prior to RT) for the treatment of nGBM 
and nAA patients. In this trial, a total of 187 patients received 
two cycles of TMZ at 200 mg/m2/day for 5 consecutive days 
every 28 days, and the objective response rate was determined 
using the bidimensional criteria on pre and postchemotherapy 
enhanced scans. A total of 162 patients were evaluable for 
response, and the ORR was 20% (95% CI 14, 26).49
A nonrandomized open-label phase II study evaluated 
the role of TMZ in combination with the antiangiogenic 
agent thalidomide for the treatment of nGBM. A total of 
44 patients were treated with surgery followed by RT, and 
subsequently 19 patients (43%) received thalidomide alone 
and 25 (57%) received thalidomide with TMZ. Only two 
patients (8%) in the combined thalidomide/ TMZ group 
achieved an ORR.50
A phase I trial assessed the safety and efficacy of combin-
ing TMZ with procarbazine (PCB) for the treatment of glioma 
patients. This trial enrolled 16 nGBM, seven nAA, and five 
low-grade glioma patients. Although this trial was designed 
to evaluate the safety of the TMZ/PCB combination, a 36% 
ORR was observed.51
Neoadjuvant TMZ in combination with carmustine was 
evaluated for the treatment of analplastic gliomas in a phase II 
trial. A total of 41 patients received four cycles of neoadjuvant 
TMZ and carmustine prior to RT. Histology included nAA 
(81%), newly diagnosed anaplastic oligodendroglioma 
(12%), and mixed tumors (7%). The ORR was 29%, with a 
2% CR and a 27% PR.52 Despite a reasonable response rate, 
this combination chemotherapy regimen was associated with 
considerable myelosuppression.
rGBM and rAA
Two pivotal trials have evaluated the response of patients 
with rGBM to TMZ treatment26,53 and one trial has evaluated 
rAA.54 The ORR to TMZ in rGBM in the two trials was 5% 
and 8%, respectively,26,53 which was similar to an ORR of 
6% among rGBM patients treated with a variety of chemo-
therapeutic agents including nitrosoureas.55 The ORR with 
Table 2 Nonhematologic toxicities associated with TMZ
Grade 1 Grade 2 Grade 3 Grade 4 Grade 5
Nausea Loss of appetite without 
alteration in eating habits
Decreased oral intake without weight 
loss, dehydration or malnutrition; iv 
fluids indicated 24 hrs
Inadequate oral fluids or 
caloric intake: IV fluids, tube 
feeds or TPN required 24 hrs
Life-threatening 
consequences
Death
vomiting 1 episode in 24 hrs 2–5 episodes in 24 hrs, IV fluids 
required 24 hrs
6 episodes in 24 hrs, IV fluids 
or TPN required 24 hrs
Life-threatening 
complications
Death
Fatigue Mild fatigue over baseline Moderate fatigue causing difficulty 
with performing ADL
Severe fatigue interfering with 
ADL
Disabling fatigue
Abbreviations:   ADL, activities of daily living; iv, intravenous; TPN, total parenteral nutrition.
Table 3 Hematologic toxicities associated with TMZ
Grade 1 Grade 2 Grade 3 Grade 4 Grade 5
Leucocyte count (109/L) LLN-3 3.0–2.0 2.0–1.0 1.0 Death
Lymphocyte count (109/L) LLN-0.8 0.8–0.5 0.5–0.2 0.2 Death
Neutrophils(109/L) LLN-1.5 1.5–1.0 1.0–0.5 0.5 Death
Hemoglobin (g/dL) LLN-10 10–8 8–6.5 6.5 Death
Platelets (109/L) LLN-75 75–50 50–25 25 Death
Notes: LLN, less than lower limit of normal.Core Evidence 2009:4 100
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TMZ among rAA patients, however, was 35%,54 an outcome 
that compared favorably with a 14% ORR for patients treated 
with other chemotherapeutic agents.55 This trial served as the 
foundation for the approval of TMZ in 1999 in Europe and 
the US for the treatment of rAA. Although objective response 
rates in rGBM patients treated with TMZ were less impres-
sive than data derived from rAA patients, a study by Yung and 
colleagues comparing efficacy of TMZ with PCB noted that 
the overall response (PR + stable disease) was higher among 
patients treated with TMZ [51/112 patients (45.6%) versus 
37/113 (32.7%), P = 0.049].26 The ORR (PR + CR) however 
was no different between the two groups, with six PR with 
both TMZ and PCB, and no CR with either agent.26
Progression-free survival
nGBM and nAA
TMZ has been shown to increase the percentage of progression-
free patients with malignant gliomas at the 6-month time point 
following initiation of treatment. Several trials have evaluated 
the effect of TMZ on PFS6m either alone or in combination 
with other drugs for the treatment of nGBM and nAA,28,56 
including a phase II trial that investigated the role of TMZ 
in combination with lomustine for the treatment of nGBM. 
Lomustine was administered at a dose of 110 mg/m2 (day 1) 
with TMZ 100 mg/m2/day (days 2–6) plus involved field RT to 
31 patients with nGBM. The PFS6m for this group was 61.3%.56 
The role of neoadjuvant TMZ was investigated in another phase 
II trial where TMZ was given after a biopsy was performed and 
prior to RT. The ORR to TMZ was therefore assessed without 
the confounding effects of surgery or radiotherapy.49
Several in-vitro studies suggested that TMZ may act as a 
radiosensitizer when administered concurrently with RT.57,58 
In order to investigate whether TMZ administered during 
and after RT provides a clinical benefit compared with RT 
alone, a pilot phase II trial was conducted by Stupp et al.59 
A total of 64 patients with nGBM from two institutions were 
randomized to receive TMZ 75 mg/m2/day for 42 consecutive 
days during RT (60 Gy in 30 fractions), followed by adjuvant 
TMZ 150–200 mg/m2/day for 5 consecutive days every 
28 days. Patients received up to six cycles of adjuvant TMZ 
following concurrent treatment. Although this trial did not 
report PFS6m or median progression-free survival (mPFS), 
a mOS of 16 months, a 1-year survival of 58%, and a 2-year 
survival of 31 % were reported.59
A similar phase II trial examined the efficacy of TMZ in 
combination with RT followed by adjuvant TMZ.60 In this 
trial 130 patients (110 assessable) were randomly assigned 
to receive either TMZ 75 mg/m2/day with concurrent RT 
(60 Gy in 30 fractions; n = 57) followed by six cycles of 
adjuvant TMZ 150 mg/m2/day on days 1–5 and days 15–19 
every 28 days, or RT alone (60 Gy in 30 fractions; n = 53). 
The administration of TMZ on days 15–19 of each adjuvant 
cycle represented a 50% increase in TMZ dose compared to 
the conventional regimen. The PFS6m observed in this trial 
was 67.1 % in the TMZ/RT group compared with 44.9% in 
the RT only group. The 1-year survival for patients treated 
with TMZ and RT was 56.3% (95% CI 44.12, 71.60), an 
outcome that was comparable to that observed in the trial 
conducted by Stupp et al.59
The encouraging phase II results using concurrent and 
adjuvant TMZ for the treatment of nGBM led to a definitive 
phase III trial conducted by EORTC and the National Cancer 
Institute of Canada Clinical Trials Group (NCIC CTG).28 In 
this large randomized international trial, 286 patients were 
assigned to receive RT alone and 287 patients were assigned 
to receive RT plus TMZ followed by adjuvant TMZ for a 
maximum of six cycles. RT consisted of 60 Gy administered in 
30 fractions, and chemotherapy consisted of TMZ administered 
concurrently during RT at a dose of 75 mg/m2/day. The 
adjuvant TMZ regimen was 150 mg/m2/day for 5 days on 
cycle 1 and if tolerated, increased to 200 mg/m2/day for 5 days 
every 28 days on cycles 2 and thereafter. Patients receiving 
concurrent and adjuvant TMZ had a significantly better PFS6m 
(53.9%, CI 48.1, 59.6), compared with those receiving RT 
alone (36.4%, CI 30.8, 41.9).28
rGBM and rAA
Three pivotal phase II trials have established a role for TMZ 
in the treatment of patients with rGBM and rAA.26,53,54 These 
trials were the first to adopt PFS6m as a primary endpoint. 
Earlier trials utilizing the ORR as an endpoint may have 
underestimated clinical efficacy because clinical and quality of 
life benefits may be derived without radiographic evidence of 
tumor regression.17,18 The first two trials evaluated the efficacy 
of TMZ in rGBM and showed a PFS6m of 18%53 and 21% 
(versus 8% for PCB)26 respectively, and a corresponding ORR 
of only 8%53 and 5%.26 Since a PFS6m of  10% was deemed 
indicative of adequate drug activity,61,62 these trials demon-
strated a positive role for TMZ in rGBM. TMZ was subse-
quently approved in Europe for the treatment of rGBM.
A third trial evaluating TMZ in rAA enrolled 162 patients 
and demonstrated an impressive PFS6m of 46%.54 The 
ORR among this group of rAA patients was 35%, results 
that compared favorably with an MD Anderson Cancer 
Center database of rAA patients who received various 
chemotherapeutic agents and had a PFS6m of only 31%.55 Core Evidence 2009:4 101
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This led to the accelerated approval of TMZ in 1999 by the 
FDA and the European Medicines Agency (EMEA) for the 
treatment of rAA.
TMZ has also been investigated in combination with 
other chemotherapeutic and targeted agents in an attempt to 
improve its efficacy against malignant gliomas. A recent North 
American Brain Tumor Consortium phase II trial combined 
TMZ with the antiangiogenic agent thalidomide for rGBM 
patients.63 This trial enrolled 44 rGBM patients (43 patients 
were evaluable) for clinical efficacy and safety of TMZ. 
Eligible patients had rGBM after standard surgical resection 
and RT, and 82% of patients were chemotherapy-naïve at the 
time of relapse. TMZ was given in the standard 5-day cycle 
(150–200 mg/m2/day on days 1–5 every 28 days) and thalido-
mide 400 mg was given orally on days 1–28, and escalated to 
1200 mg if tolerated. This trial demonstrated a PFS6m of 24%, 
suggesting that the combination was not superior to single 
agent TMZ when used for the treatment of rGBM.63
MGMT has been implicated as one of the mechanisms 
of tumor resistance to alkalytator and methylator chemo-
therapies.44,45 Depletion of MGMT has been demonstrated 
in vitro by cisplatin and continuous TMZ administration.64 
TMZ in combination with cisplatin was therefore evaluated 
for the treatment of rGBM patients.65 In this phase II study, 
50 patients with rGBM (49 patients were assessable) were 
given TMZ 130 mg/m2 bolus on day 1, followed by 70 mg/m2 
every 12 hours on days 2–5, repeated every 4 weeks. Cisplatin 
was given in a dose of 75 mg/m2 on day 1 only of each 
4-week cycle. The dose of TMZ was escalated to a cumula-
tive maximum of 1000 mg/m2 over 5 days in the absence of 
hematologic toxicity. This regimen resulted in a PFS6m of 
34% (95% CI 23, 50) and a median PFS of 18.4 weeks, and 
was associated with an acceptable toxicity profile.65
Another phase II trial evaluated a TMZ and cisplatin 
combination regimen in rGBM and rAA patients.66 
Thirty-three patients (20 rGBM and 13 rAA patients) were 
treated with cisplatin 40 mg/m2 intravenously on days 1 and 
2 plus TMZ 200 mg/m2/day on days 2–6 (24 hours after first 
cisplatin dose), and cycles were repeated every 4 weeks. This 
regimen resulted in a 52% PFS6m and a mPFS of 33 weeks 
(29.3 weeks for GBM and 39.5 weeks for AA). However, the 
higher PFS6m and mPFS demonstrated in this trial is likely 
due to the proportion of rAA patients included.66
Liposomal doxorubicin has demonstrable activity in a 
variety of malignancies,67 and its combination with TMZ 
was recently explored for the treatment of rGBM.68 In this 
phase II trial, 22 patients with rGBM were given liposomal 
doxorubicin 40 mg/m2 on day 1 with TMZ 200 mg/m2/day 
on days 1–5 administered in 4-week cycles. This regimen 
produced a PFS6m of 32% and an mPFS of 3.2 months.68
The matrix metalloproteinase inhibitor marimastat has 
also been investigated in combination with TMZ for the 
treatment of rGBM. Evidence derived from in-vitro data 
indicated that marimastat can inhibit glioma cell invasion, 
and for this reason its combination with TMZ is theoretically 
appealing.69 A total of 44 patients with rGBM received TMZ 
(200 mg/m2/day, days 1–5) and marimastat (50 mg/day, days 
8–28) in a 28-day cycle for two cycles. The PFS6m in this 
group of patients was 39% and mPFS was 17 weeks. This 
study was complicated by a 47% incidence of joint and 
tendon pain that resulted in the removal of 11 % of patients 
from the study. The authors concluded that while the activity 
of this regimen appeared promising, further refinements were 
needed to minimize the toxic side effects.70
TMZ maintains activity in rGBM even at second 
recurrence. A small Italian study demonstrated a PFS6m 
of 24% when TMZ (standard 5-day regimen) was given 
to a group of 42 patients with rGBM at the time of second 
relapse.71 Although these patients were heavily pretreated 
with various chemotherapeutic agents, TMZ remained a 
viable therapeutic option for this group of patients.
Continuous daily dosing or “dose-dense” TMZ repre-
sents an attractive treatment approach based on in-vitro 
data demonstrating rapid MGMT enzyme depletion with 
continuous exposure to TMZ.72 A small Memorial Sloan-Ket-
tering Cancer Center phase II trial evaluated continuous TMZ 
in recurrent malignant gliomas. This trial enrolled 35 patients 
(28 with rGBM, three with rAA, two with recurring anaplastic 
oligodendroglioma, and two with recurring anaplastic 
oligoastrocytomas) to receive TMZ 75 mg/m2/day for 42 
days, in 70-day cycles. The PFS6m for the entire group was 
27%, while PFS6m for the subgroup of GBM patients was 
19%.73 Despite the acceptable PFS6m, the data failed to 
show superiority of this approach over the standard 5-day 
TMZ regimen.
Overall survival
nGBM and nAA
The definitive EORTC/NCIC phase III trial has demonstrated 
conclusively that TMZ can prolong mOS in nGBM patients 
by 2.5 months.28 These results confirm earlier phase II 
trials that demonstrated a survival advantage for TMZ in 
newly diagnosed malignant astrocytomas.56,60 TMZ given 
immediately in the postoperative setting and prior to 
neoadjuvant RT for nGBM and nAA patients resulted in 
a mOS of 10 months (16 months for responding patients Core Evidence 2009:4 102
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versus only 3 months for nonresponders).49 Assessing TMZ 
efficacy in the neoadjuvant setting provides an advantage in 
that the benefit derived is not confounded by an RT effect 
or the effect of other chemotherapeutic agents.
The promising results obtained with neoadjuvant 
TMZ treatment led to further refinements of TMZ dosing 
schedules for the treatment of nGBM. A pilot phase II trial 
conducted by Stupp and colleagues59 assessed the novel 
approach of concurrent TMZ/RT followed by adjuvant 
TMZ given to 69 nGBM patients.59 The mOS reported in 
this study was 16 months. Another phase II trial compared 
TMZ + RT followed by adjuvant TMZ (150 mg/m2/day on 
days 1–5 and 15–19) with RT alone. The mOS reported 
for the TMZ/RT group was 13.4 versus 7.7 months for the RT 
group (P = 0.001).59 The phase II data reported by Stupp 
et al59 led to a definitive phase III trial conducted by the 
EORTC/NCIC in order to confirm the benefit of this novel 
regimen for the treatment of nGBM patients.28 As noted 
earlier, this trial enrolled 573 patients (286 patients in the RT 
arm and 287 patients in the TMZ/RT arm) most of whom 
were pathologically-proven GBM patients (93% in the RT 
arm and 92% in the TMZ/RT arm). At a median follow up 
of 28 months, 84% of the enrolled patients had died. For the 
patients who received concurrent and adjuvant TMZ, their 
unadjusted hazard ratio for death was 0.63 (95% CI 0.52, 
0.75; P  0.007 by the log-rank test), which translates into 
a 37% reduction in the risk of death for nGBM patients 
receiving concurrent and adjuvant TMZ, compared with 
those receiving RT alone. The mOS reported for the TMZ/RT 
group was 14.6 (95% CI 13.2, 16.8) versus 12.1 months 
(95% CI 11.2, 13.0) for RT alone, which translates into a 
2.5-month increase in mOS for the TMZ/RT group compared 
with the RT only group. This was the first phase III trial to 
demonstrate a statistically significant and clinically meaning-
ful survival advantage with the addition of chemotherapy to 
standard RT for nGBM patients.
Several other studies have used TMZ with other agents 
in an attempt to further improve the survival statistics. 
A phase II study enrolling 45 patients (38 with GBM and 
seven with AA) combined TMZ (150 mg/m2/day on days 
1–5) with irinotecan (150 mg/m2/day on days 6 and 17) given 
every 4 weeks for a maximum of six cycles.74 Patients with 
GBM had a mOS of 12.8 months but this regimen was 
associated with a high rate of toxicity and failed to improve 
the survival statistics over TMZ alone for the treatment of 
nGBM and nAA patients.
Another phase II trial treated 31 patients with a 
combination of involved field RT (60 Gy in 30 fractions), 
lomustine (100 mg/m2 on day 1), and TMZ (100 mg/m2/day 
on days 2–6) every 4 weeks for up to six cycles. The reported 
mOS was 22.6 months and the regimen was associated with 
acceptable toxicity, indicating that further investigation of 
this approach may be warranted.56
rGBM and rAA
TMZ has established activity in the treatment of rGBM and 
rAA patients. Three pivotal phase II studies demonstrated 
radiographic response to TMZ in rGBM and rAA patients 
but failed to prolong mOS compared with historic 
databases of patients treated with other chemotherapeutic 
agents.26,53–55
The first study enrolled 138 rGBM patients and reported 
an mOS of 5.4 months.53 Patients treated with a variety of 
chemotherapeutic agents in a study conducted by Wong and 
colleagues55 had a similar mOS of 5.8 months. Another trial 
enrolled 225 rGBM patients randomized to PCB or TMZ. 
Patients receiving TMZ treatment had a mOS of 7.3 months 
compared with 5.8 months in those treated with PCB. This 
1.5-month increase in mOS for TMZ-treated patients failed 
to reach statistical significance.26 A further trial examining 
the role of TMZ in rAA enrolled 162 patients and reported a 
mOS of 13.6 months.54 Data derived from the trial conducted 
by Wong and colleagues of patients receiving a variety of 
chemotherapeutic agents reported a mOS of 11 months 
among rAA patients.55 Despite the failure of TMZ to improve 
survival outcome, these trials nevertheless demonstrated 
improvements in the novel endpoint PFS6m as well as 
HRQoL, leading to the approval of TMZ for the treatment 
of rGBM and rAA patients.
Combining TMZ with other agents has also been 
investigated for the treatment of rGBM and rAA patients. 
For example, a small trial in 22 patients with rGBM reported 
a mOS of 8.2 months for the combination of doxorubicin 
with TMZ.68 Another study combining marimastat with TMZ 
reported a mOS of 45 weeks.70
To date, combining TMZ with other agents does not 
appear to confer an additional survival advantage over 
TMZ alone for the treatment of recurrent malignant astro-
cytomas. Table 4 summarizes the effect of TMZ on various 
trial endpoints when used for the treatment of malignant 
astrocytomas.
HrQoL
The addition of TMZ to the standard treatment approaches 
of surgery and RT has been shown to impact positively on 
HRQoL among recurrent glioma patients. Two studies by Core Evidence 2009:4 103
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Osoba and colleagues75,76 examined the effect of TMZ on 
HRQoL in patients with rAA and rGBM.
The first study calculated changes from baseline scores of 
seven HRQoL domains (role and social functioning, global 
quality of life, visual disorder, motor disorder, communica-
tion deficit, and drowsiness) in rAA patients treated with 
TMZ.76 These HRQoL domains were assessed every 4 weeks 
at each TMZ treatment cycle, and changes were compared 
to pretreatment (baseline) scores. This study demonstrated a 
significant improvement (defined as an increase 10 points 
from baseline scores) in all HRQoL domains following TMZ 
treatment. These improvements correlated with freedom 
from disease progression, and dropped sharply at the time 
of disease progression.76 Since TMZ is known to delay the 
time to tumor progression among recurrent glioma patients, 
this may in part explain the improvements in HRQoL scores 
seen with TMZ treatment.
A large phase II trial comparing the efficacy of TMZ 
with PCB in rGBM also included assessments of HRQoL 
scores. In this trial, 225 patients were randomly assigned to 
receive either TMZ (n = 112) or PCB (n = 113) at the time 
of first relapse.26 Patients receiving TMZ scored consistently 
higher on seven HRQoL domains, and this improvement was 
maintained until disease progression. Since TMZ was given 
on every 5 of 28 days while PCB was given daily for 28 days, 
the authors commented that the improvement in HRQoL 
may have been related to toxicity associated with daily PCB 
administration rather than to TMZ benefit. However, the study 
also demonstrated that TMZ delayed time to tumor progres-
sion compared with PCB, a parameter that closely correlates 
with maintenance or improvement in HRQoL.26 Whether or 
not TMZ directly impacts HRQoL parameters, its favorable 
toxicity profile compared with other chemotherapeutic agents 
likely plays a role in maintaining quality of life in a population 
that has to endure many potential adverse drug events.
Patients enrolled in a recent EORTC/NCIC phase III 
trial examining the role of concurrent TMZ/RT followed 
by adjuvant TMZ among nGBM patients were also 
assessed for changes in the predefined HRQoL measures 
at baseline and every 3 months following treatment until 
disease progression. Changes in HRQoL were calculated 
among patients receiving concurrent TMZ/RT followed by 
adjuvant TMZ and those receiving RT alone. HRQoL was a 
secondary endpoint for this study and was calculated based 
on the EORTC quality of life questionnaire Core-30 and the 
EORTC BN-20. The parameters used to measure HRQoL 
Table 4 Evidence for TXZ efficacy in malignant astrocytomas
nGBM/nAA rGBM/rAA Reference
Orr Neoadjuvant TMZ: 20% 
TMZ + TLD: 8%  
TMZ (GBM, AA and LGG): 
36%
Single agent TMZ for rGBM: 5% 
Single agent TMZ for rGBM: 8% 
Single agent TMZ for rAA: 35% 
rGBM: 6%  
rAA: 14%
Brada et al;49   Yung et al26 
Baumann et al;53 Brada et al50 
Newlands et al;51   Yung et al54 
wong et al55
PFS6m TMZ/rT + adjuvant TMZ: 
67.1 % 
rT alone: 44.9% TMZ/rT + 
adjuvant TMZ: 53.9%  
rT alone: 36.4%
rGBM: 18%  
rGBM: 21 % vs 8% for PCB 
rAA: 46% 
rGBM: 15%  
rAA: 31 %
Athanassiou et al60  
Brada et al54  
Yung et al26,54
Stupp et al28 
wong et al55
mOS nGBM/nAA (neoadjuvant 
TMZ): 10 mo  
nGBM (TMZ/rT + TMZ): 
16 mo nGBM  
(TMZ/rT + TMZ): 13.4 mo   
rT alone: 7.7 mo
rGBM: 5.4 mo  
rGBM: 7.3 mo vs 5.8 mo for 
PCB  
rAA: 13.6 mo
Brada et al;49,50 Stupp et al58 
2002;   Yung et al;26 Athanasiou, 
et al;54   Yung et al108
Stupp et al28
nGBM (TMZ/rT + TMZ): 
14.6 mo  
rT alone: 12.1 mo
rGBM: 5.8 mob  
rAA: 11 mob  
All patients: 7.0 mob
wong et al55
Notes:   aHistoric database of patients treated with multiple chemotherapeutic agents in a trial conducted by wong and colleagues55 is used for comparison.
bData converted from weeks to months for ease of comparison using the formula (weeks × 7)/30 = months.
Abbreviations: Car, carmustine; Cis, cisplatin; GBM, glioblastoma; LGG, low grade glioma; mo, months; mOS, median overall survival; nAA, newly diagnosed anaplastic astrocy-
toma; nGBM, newly diagnosed GBM; Orr, objective radiographic response; PCB, procarbazine; PFS6m, progression-free survival at 6 mo; rGBM, recurrent GBM; rAA, recurrent 
anaplastic astrocytoma; rT, radiotherapy; TLD, thalidomide; TMZ, temozolomide.Core Evidence 2009:4 104
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were fatigue, overall health, social function, emotional 
function, future uncertainty, insomnia, and communication 
deficit. Improvement in HRQoL was defined as an increase 
of 10 points compared with baseline. Overall, the study 
concluded that the addition of TMZ to RT did not impair the 
HRQoL measures compared with RT alone.77
Safety and tolerability
TMZ therapy has been consistently shown to be relatively 
safe and reasonably well tolerated in multiple trials for 
the treatment of malignant gliomas. The most commonly 
tested dosing schedule is a standard 5-day regimen of 
150–200 mg/m2/day, which was developed in the early 
1990s by Newlands and coworkers.78 In an early phase I trial, 
TMZ given as asingle bolus of 50 mg/m2, and subsequently 
escalated to 1200 mg/m2, resulted in no antitumor activity 
but was associated with myelosuppression as a major dose-
limiting toxicity.51 The 5-day regimen was subsequently 
developed and given as a starting dose of 150 mg/m2/day 
for 5 days, in 28-day cycles and escalated to 200 mg/m2/day 
for 5 days on subsequent cycles if tolerated. This regimen 
was associated with clinical activity as opposed to the 
single TMZ dose and furthermore, 17% (two CR and two 
PR) of 23 patients demonstrated an ORR.51 The side effects 
associated with this regimen included nausea and vomiting 
that were controlled with 5HT3-antagonists. There was also 
little cumulative toxicity with this regimen and patients 
tolerated repeated cycles for up to 3 years.51
The first trial to examine the safety and tolerability 
of TMZ given concurrently and adjuvantly with RT was 
conducted by Stupp and colleagues in 2002. During the 
concomitant phase of treatment, grade lll or lV neutropenia 
or thrombocytopenia was observed in four patients (6%) 
each. Grade lll or lV lymphocytopenia was a very common 
side effect observed with this regimen, with 79% of patients 
suffering from this toxicity during the concurrent TMZ/RT 
phase of treatment. Three patients developed infections: 
two had Pneumocystis carinii pneumonia (PCP), and one 
developed osteomyelitis. Both patients with PCP had grade lll 
or lV neutropenia and lymphocytopenia at the time of the 
infection.58 Following the development of PCP in these two 
patients, pentamidine prophylaxis was introduced in the trial 
to be given to patients receiving concurrent treatment and 
no further PCP episodes were observed. During the adjuvant 
phase of treatment grade lll or lV neutropenia occurred in 2% 
of patients, while grade lll or lV thrombocytopenia occurred 
in 6% of patients. Only 2% of patients developed grade lll or 
lV anemia during adjuvant TMZ administration.
Nonhematologic toxicities during both phases of 
treatment were well tolerated and included nausea and 
vomiting (managed by standard antiemetics), moderate 
to severe fatigue, and rash resulting in discontinuation of 
treatment. One patient developed intracranial hypertension, 
refractory seizures, and loss of vision, all of which were 
considered delayed radiation-induced adverse events rather 
than side effects related to TMZ.
The EORTC/NCIC phase III trial enrolled the largest 
number of patients to date treated with TMZ.28 It therefore 
provided a large sample size for assessing safety and 
tolerability of TMZ in combination with RT and as a single 
agent in the adjuvant setting. There were no grade lll or 
lV hematologic toxic effects noted among those treated 
with RT alone. During the concurrent RT/TMZ treatment, 
12 patients (4%) experienced grade lll or lV neutropenia 
while grade lll or lV thrombocytopenia occurred in nine 
patients (3%). Grade lll or lV hematologic toxicities were 
reported in 19 patients (7%) (Table 5).28
Overall, TMZ given concurrently with RT or as a single 
agent is well tolerated, with noncumulative myelotoxicity as 
the main dose-limiting side effect. Nonhematologic toxicities 
are usually well tolerated and include mild-to-moderate 
fatigue, constipation, nausea, and vomiting.
Prognostic factors
Prognostic determinants of survival for patients with malignant 
astrocytomas include tumor grade and histology (ie, GBM or 
AA), age, Karnofsky performance status (KPS), and MGMT 
promoter methylation status.79,80 The most important prognos-
ticfactor and the one that most closely predicts mOS is tumor 
grade. Patients with GBM (WHO grade IV) fare worse than 
those with the lower grade AA (WHO grade III).1 Although 
GBM occurs on average among patients 10 years older than 
those with AA, age is likely to be an independent negative 
prognostic factor1 Among elderly patients (75 years) with 
GBM, the 2-year survival is only 1.4% compared with 29.8% 
for patients aged between 20 and 44 years old.1 Patients with a 
lower performance status fare worse than those who are fully 
functional, and have a better KPS.
Several trials have evaluated the role of the extent of 
surgical resection in prolonging survival among malignant 
astrocytoma patients.81,82 Although some trials have shown that 
patients who have undergone gross total resection have better 
outcomes compared with those undergoing subtotal resection 
or biopsy only, these trials are fraught with confounding 
variables.83,84 For example, patients who underwent biopsy 
only were typically of older age and with worse KPS scores. Core Evidence 2009:4 105
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In such instances, multivariate analysis revealed that the extent 
of surgery did not correlate with improved survival.85
Curran and colleagues86 have developed a recursive 
partitioning analysis (RPA) model of treatment and 
pretreatment-related prognostic variables for patients with 
malignant gliomas86,87(Table 6).
The RPA model was applied to the 64 patients enrolled 
in the phase II trial comparing RT with RT/TMZ for nGBM 
patients.87 Median survival among these patients was 
24 months for RPA class III, 14 months for RPA class IV, 
and 9 months for RPA class V, which compared favorably 
with a Radiation Therapy Oncology Group database.87 This 
was an incentive for conducting a larger phase III randomized 
trial that resulted in a new standard of care for the treatment 
of nGBM.28 The RPA methodology in this study was also 
used to evaluate the effect of adding TMZ to RT on median 
survival time. Among patients in the RPA class III receiving 
RT + TMZ, there was a gain of 7 months in median survival 
time and of 24% in the 2-year survival time (P = 0.006). For 
this subset of patients, adding TMZ to RT resulted in a 43% 
probability of survival at 2 years.28 The addition of TMZ to 
RT still maintained its benefit among RPA class IV patients, 
more than doubling the 2-year survival rates compared with 
RT alone (P = 0.0001). The gain among the RPA class V 
patients was statistically insignificant (P = 0.054), indicating 
that such patients with poor prognostic variables are least likely 
to benefit from addition of TMZ to RT (Table 7).28 However, 
this should not be taken as a reason to withhold TMZ treatment 
from RPA class V patients, since it is not known whether they 
derive benefits in other variables such as HRQoL.
Ongoing clinical development
Several trials are ongoing to evaluate the efficacy of 1 TMZ 
with various chemotherapeutic as well as targeted agents. For 
example, a phase I trial evaluating the safety and tolerability 
of adding everolimus (RAD001), an inhibitor of mammalian 
Table 5 Grade 3 or 4 hematologic toxic effects [% (n)] in patients treated with temozolomide (adapted from Stupp et al28)
Concomitant TMZ/RT (n = 284) Adjuvant TMZ (n = 223) Entire study perioda (n = 284)
Leukopenia 7 (2) 11 (5) 20 (7)
Neutropenia 12 (4) 9 (4) 21 (7)
Thrombocytopenia 9 (3) 24 (11) 33 (12)
Anemia 1 (1) 2 (1) 4 (1)
Any 19 (7) 32 (14) 46 (16)
Notes: aThe entire study period is defined as the period from study entry to 7 days after disease progression.
Abbreviations:  rT, radiotherapy;   TMZ, temozolomide.
Table 6 Original and adapted rTOG/EOrTC rPA class iii–v (adapted from Mirimanoff et al87)
RPA class RTOG (original) EORTC
iii    age, years tumor type mental status 
performance status
50 Anaplastic astrocytomas Abnormal 50 Glioblastoma multiforme 
wHO PS 0
Or    age, years tumor type performance 
status
50 Glioblastoma multiforme KPS 90–100
iv    age, years tumor type performance 
status
50 Glioblastoma multiforme KPS  90 50 Glioblastoma multiforme 
wHO PS 1–2
Or    age, years tumor type performance 
status treatment mental status
50 Anaplastic astrocytomas KPS 70–100  3 from 
time of first symptom to start of treatment
50 Glioblastoma multiforme 
Complete/partial surgery 
MMSE  27
Or    age, years tumor type mental state 
treatment status
50 Glioblastoma multiforme Good neurologic 
function Surgical resection
v    age, years tumor type performance 
status mental status treatment status
50 Glioblastoma multiforme KPS 70–100 
Neurologic function that inhibits the ability to work 
Surgical resection or biopsy only followed by at least 
54.4 Gy radiotherapy
50 Glioblastoma multiforme 
MMSE  27 Biopsy only
Or    age, years tumor type performance 
status mental status
50 Glioblastoma multiforme KPS  70  
Normal
Abbreviations: EOrTC, European Organization for research and Treatment of Cancer; KPS, Karnofsky performance status; MMSE, Mini Mental State Evaluation; rPA, recursive 
partitioning analysis; rTOG, radiation Therapy Oncology Group;   wHO PS, world Health Organization performance status.Core Evidence 2009:4 106
Omar and Mason Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
target of rapamycin (mTOR), to TMZ in nGBM patients is 
currently being conducted by the NCIC CTG.88
Continuous daily “dose-dense” TMZ is also currently 
under investigation for the treatment of recurrent malignant 
gliomas. Patients with recurrent malignant gliomas who 
have shown evidence of progression on the 5-day TMZ 
regimen are candidates for this trial. Patients receive TMZ 
at 75 mg/m2/day in 28-day cycles, and the cycles are repeated 
for up to a year if tolerated.89
In order to overcome MGMT-induced TMZ resistance, 
some trials have assessed the efficacy of combination 
regimens with TMZ and O-6-benzylguanine (an MGMT 
inhibitor).90,91 To date, these trials have failed to demonstrate 
improvements in outcome compared with TMZ alone but 
further investigations are ongoing.
Economic evidence
Because TMZ is associated with high acquisition costs, it 
is important to assess whether these additional costs are 
associated with measurable benefits. A report by Wasserfallen 
and colleagues92 showed that the addition of TMZ to RT for the 
treatment of nGBM patients was eight times more expensive 
than RT alone.92 Several reports therefore assessed the costs 
of TMZ per life-year and QALY gained, and whether such 
costs were below the acceptable threshold of $US50 000 per 
life-year gained as proposed by Prosser and colleagues.92 The 
decision whether or not to reimburse TMZ treatment by payors 
may be influenced by such economic analyses of cost-1 ratios, 
especially in systems with limited healthcare resources.
Data from a phase II trial evaluating the safety and 
efficacy of concurrent and adjuvant TMZ in nGBM.59 were 
collected, and associated costs retrospectively computed.92 
The phase II trial enrolled 64 patients from two institutions, 
but only data related to 46 patients at one institution 
(University Center of Vaud, Lausanne, Switzerland) were 
analysed. Costs were computed for four separate periods: 
during concurrent TMZ and RT; during adjuvant TMZ; 
during the follow-up period and up to disease recurrence; 
and finally from disease recurrence until death.
This study showed that TMZ treatment had an average 
cost of  20 952 (eight times more expensive than RT alone). 
TMZ drug acquisition costs represented 54% of the total 
costs during the concurrent phase and 75% of the total costs 
during the adjuvant phase.93 Costs associated with the follow-
up period (after completion of adjuvant TMZ) were largely 
attributable to hospitalizations as well as brain imaging 
studies, while those associated with disease recurrence were 
mainly due to palliative care hospitalizations and further 
chemotherapy treatments. This study also reported that the 
overall cost of care associated with TMZ use for nGBM 
patients treated in this trial ranged from  10 893 to  125 275, 
with a median of  34362, and that TMZ acquisition costs 
represented 55% of this sum. The median cost per month 
of survival was  2307 and the cost of TMZ per year of sur-
vival was  27 684. Interestingly, tumor MGMT promoter 
status and extent of surgery significantly affected the costs 
associated with TMZ treatment. Patients with tumors that had 
methylated MGMT promoter had a statistically significantly 
longer follow-up period before disease recurrence compared 
with patients with tumors that had unmethylated MGMT 
promoter (19.6 ± 17.7 versus 2.3 ± 1.7 months; P = 0.049). 
The costs incurred during this longer follow-up period were 
higher ( 4793 ± 3848 versus  636 ± 633; P = 0.049), but 
the average monthly costs were similar. Patients who under-
went surgical debulking also fared better than those who 
underwent biopsy only, and had longer adjuvant periods of 
TMZ treatment (144 ± 50 versus 80 ± 24 days, P = 0.032) 
and longer survival (10.9 ± 10.7 versus 4.1 ± 4.7 months, 
P = 0.014). Interestingly, the total costs per month of survival 
for patients undergoing surgical debulking were lower than 
in those undergoing biopsy only because they required fewer 
hospitalizations despite the greater costs associated with 
TMZ use.92 This study was limited, however, by the small 
sample size and the retrospective nature of the analysis. 
Moreover, cost-effectiveness or cost-utility measures for 
TMZ in nGBM patients were not determined. Importantly, 
this study demonstrated that since concurrent and adjuvant 
TMZ was associated with a 4-month increase in median 
survival, the additional costs associated with this regimen 
would exceed the acceptable threshold of $US50 000 per 
life-year gained. The authors argued that this should not be 
a reason to withhold TMZ from a patient population with 
little or no other effective alternatives.
Another report by Wasserfallen and colleagues94 
calculated the cost effectiveness and cost utility of TMZ use 
in patients with rGBM or rAA. The median cost effectiveness 
of TMZ in this patient population ranged between  28 817 and 
Table 7 Overall survival rates by rPA class (adapted from Stupp 
et al28)
RPA class Median survival 2-year survival
Months 95% CI % 95% CI
iii 17 15–21 32 21–2
iv 15 13–16 19 15–24
v 10 9–12 11 7–16
Abbreviation: rPA, recursive partitioning analysis.Core Evidence 2009:4 107
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38450. When these cost s were weighted by the individual 
mean health status (area under the Karnofsky curve), the cost 
utility ranged from  41167 to  53369 per QALY gained. This 
figure fell below the accepted $US50 000 threshold.94
A report commissioned by the Health Technology 
Assessment Programme on behalf of the National Institute for 
Health and Clinical Excellence (NICE) in England and Wales, 
reviewed the cost effectiveness of TMZ based on a literature 
review up to the year 200095 (prior to the completion of the 
EORTC/NCIC phase III trial). The report concluded that since 
TMZ resulted in gains in PFS but not in overall survival for 
patients with rGBM, the cost per QALY gained was approxi-
mately  40 000. Furthermore, this report concluded that until 
appropriate randomized controlled trials comparing TMZ with 
other alternative therapies were conducted, no firm conclusions 
about the cost effectiveness of TMZ should be drawn.97
However, the more recent EORTC/NCIC phase III 
trial clearly demonstrated that the addition of TMZ to RT 
conferred a survival advantage for newly diagnosed GBM 
patients versus those receiving RT alone. Based on this trial, 
concurrent and adjuvant TMZ became the standard of care 
for the treatment of nGBM despite its added costs. A study 
by Mabasa and Taylor evaluated mOS and compared the cost 
effectiveness of TMZ and lomustine in patients with recur-
rent malignant glioma.96 A retrospective review of medical 
records from 41 patients was conducted. Patients receiving 
TMZ (mean 5.1 cycles) incurred a mean cost of $Can10 746, 
while those receiving lomustine (mean 3.1 cycles) incurred 
a mean cost of $Can129. Lomustine is a relatively inexpen-
sive chemotherapeutic agent that is given orally once every 
6 weeks. TMZ, a newer and more expensive agent, is given 
in a 5 consecutive day regimen every 28 days. This may 
explain the higher costs associated with TMZ treatment. 
In addition, patients with recurrent disease are generally 
resistant to chemotherapy. Since TMZ has not been shown 
to provide a survival benefit in recurrent disease versus 
lomustine, the use of the more expensive TMZ may not be 
cost effective in this patient population. The incremental 
cost-effectiveness ratio for each life-year gained with TMZ 
ranged from $Can32 247 to $Can162186. Since the study 
found no difference in mOS achieved with the two drugs, the 
authors concluded that lomustine was more cost effective than 
TMZ for the treatment of recurrent malignant glioma.96
Another study from Finland evaluated the cost 
effectiveness of TMZ versus PCV (procarbazine, lomustine, 
vincristine) treatment for rGBM patients. This study 
concluded that 1 extra life-month gained with TMZ cost 
2367, 1 extra progression-free life-month gained cost  2165, 
and the cost for each additional QALY gained was  32471 
compared with PCV. The study also concluded that TMZ 
has a “high probability” of being cost effective compared 
with PCV for rGBM patients from a Finnish healthcare payer 
perspective.97 Another small Finnish study concluded that the 
high acquisition costs of TMZ are compensated by prolonged 
home care and possibly by the ability to retain working 
capacity during TMZ treatment among patients with recurrent 
gliomas.98 Despite the additional costs associated with TMZ 
use, the improved survival and HRQoL in patients with 
malignant gliomas may justify the added costs to society.
Patient group/population
Certain populations may differentially benefit from TMZ 
treatment. For example, patients with tumors harboring 
methylated MGMT promoter were found to have better 
outcomes compared with those with tumors that had 
unmethylated MGMT promoters.99 The benefit of TMZ for 
the elderly (age 70 years) is unknown.28
MGMT methylation status
MGMT effectively reverses the cytotoxic action of TMZ and 
thus high MGMT expression levels are associated with TMZ 
resistance. Patients with silenced MGMT gene expression 
due to hypermethylation of MGMT promoters were shown 
to respond more favorably to concurrent TMZ/RT compared 
with those who had unmethylated MGMT promoters and high 
MGMT gene expression levels.99 In this study, tumor samples 
obtained from nGBM patients enrolled in the EORTC/
NCIC phase III study were analyzed for MGMT promoter 
methylation status by methylation-specific polymerase chain 
reaction techniques99 (Table 8).
Elderly patients
The treatment of elderly patients (70 years old) with newly 
diagnosed malignant gliomas remains controversial. The 
pivotal EORTC/NCIC phase III trial evaluating concurrent 
and adjuvant TMZ for nGBM excluded patients of this age.28 
One study has compared an abbreviated course of radiation 
(3 weeks) to the standard 6-week schedule in elderly patients 
diagnosed with malignant gliomas. The trial concluded 
that the 3-week schedule was better tolerated and achieved 
similar results compared with the 6-week regimen.100 Another 
phase III trial compared RT with standard supportive care 
in elderly patients with AA and GBM, and concluded that 
RT was associated with superior outcomes.101 Because 
of these findings, some neurooncologists advocate an 
abbreviated 3-week course of RT for elderly patients with Core Evidence 2009:4 108
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nGBM and nAA. It is not clear whether the addition of 
TMZ concurrently and/or adjuvantly to this shortened RT 
treatment would provide any additional advantage to this 
elderly population. A trial sponsored by the NCIC/CTG 
is currently exploring the benefit of adding TMZ to RT in 
patients aged 65 years.
Another phase III trial assessed the efficacy of TMZ alone 
instead of RT in a group of 32 elderly patients. TMZ treatment 
resulted in a PR rate of 31%, stable disease in a further 41 % of 
patients, while 28% had evidence of progressive disease. This 
cohort of patients achieved a mOS of 6.2 months (13.3 months 
among those achieving a PR), which compares favorably 
with median survival associated with RT alone.102 In addition, 
TMZ treatment was associated with a relatively mild and often 
predictable side effect profile, which makes it an attractive 
treatment option for this frail patient population.102 A further 
retrospective study comparing TMZ alone (150 mg/m2 for 5 days 
every 28 days) with RT alone in 86 elderly patients with newly 
diagnosed malignant glioma reported a higher median survival 
among those treated with TMZ alone, but the difference did not 
reach statistical significance (6.0 versus 4.1 months).103
Dosage, administration,  
and formulation
TMZ is used for the treatment of newly diagnosed as well as 
recurrent GBM and AA. Based on the EORTC/NCIC trial, 
TMZ is given concurrently with RT at 75 mg/m2 followed 
by a minimum of six cycles of adjuvant TMZ. Adjuvant 
TMZ is administered at 150 mg/m2 for 5 days on cycle 1 and 
200 mg/m2 from cycle 2 onward provided blood counts are 
adequate. The cycles are repeated every 28 days.
The management approach for patients with rAA is 
very similar to rGBM.104 Based on a trial by Yung et al54 
demonstrating an ORR rate of 35% to TMZ, this agent is 
frequently employed for the treatment of rAA.54
When treating recurrent disease, TMZ is administered 
daily for 5 days similar to the adjuvant regimen mentioned 
above. On the other hand, nAA is typically treated with 
surgical resection followed by conformal RT with or without 
concurrent TMZ. The addition of concurrent TMZ is of no 
proven value in the treatment of nAA because of the lack 
of a RCT showing superiority of this approach over RT 
alone.105 An international collaborative trial that will answer 
this question is underway.
TMZ is available in capsules of 5, 20, 100, and 250 mg. 
It achieves approximately 100% bioavailability after oral 
administration. In addition, TMZ achieves excellent blood-
brain barrier penetration and the measured cerebrospinal 
fluid area under the curve (AUC) is typically 20%–40% of 
the plasma AUC.106
Place in therapy
Based on a number of trials, TMZ is quickly becoming a 
first-line agent for the treatment of malignant astrocytomas, 
both because of its proven efficacy as well as its safety profile. 
Concurrent TMZ and RT followed by adjuvant TMZ is 
currently the standard of care for nGBM. The role of TMZ for 
the management of nAA as well as for recurrent disease is less 
well defined at present but is widely used by neurooncologists 
for the first-line treatment of these disease entities.
In patients with rGBM, TMZ is associated with an 
increase of up to 6 months in PFS compared with PCB. 
Patients with rAA treated with a variety of chemotherapeutic 
agents achieved a PFS6m of 31%,55 while rAA patients 
treated with TMZ in a phase II trial achieved a PFS6m 
of 46%. The figures from these two trials are difficult to 
compare because of the differences in baseline patient 
characteristics. The worse outcome recorded in the trial 
conducted by Wong et al55 may be explained by the high 
proportion of patients with multiple recurrences and therefore 
with poorer prognoses.
Patients with rGBM and rAA had better HRQoL scores 
after treatment with TMZ. HRQoL was also not compromised 
in nGBM patients treated with concurrent TMZ and RT 
followed by adjuvant TMZ.
Concurrent TMZ with RT followed by adjuvant TMZ 
results in a 2.5-month prolongation of median survival 
among nGBM patients compared with patients receiving RT 
alone. More importantly, studies show that the probability 
of surviving to 2 years after diagnosis was only 1 in 10 for 
nGBM patients treated with RT alone, while patients treated 
with concurrent and adjuvant TMZ had a 1 in 4 chance of 
surviving to the 2-year time point.
Table 8 Effect of MGMT promoter methylation status on PFS and 
OS among patients receiving concurrent temozolomide/radiotherapy 
versus radiotherapy alone (adapted from Hegi et al99)
Clinical endpoint TMZ + RT (n = 106) RT (n = 100)
Methylated MGMT (n) 46 46
PFS6m (%) 47.8 68.9
2-year OS (%) 22.7 46.0
Unmethylated MGMT (n) 54 60
PFS6m (%) 35.2 40.0
2-year OS (%) <2 13.8
Abbreviations: MGMT, O-6-methylguanine-DNA methyltransferase; OS, overall survival; 
PFS6m, progression-free survival at 6 months; rT, radiotherapy; TMZ, temozolomide.Core Evidence 2009:4 109
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Newly-diagnosed patients with a methylated MGMT 
promoter as well as those in RPA class III (age 50 years 
and PS of 0) seem to benefit the most from the addition of 
TMZ. Further studies are clearly needed to further refine the 
dosing schedules as well as identify ideal agents to be used 
in combination with TMZ in order to improve outcomes for 
patients with malignant glioma.
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